

Website Supplemental Information

Page 1- Supplemental Information: Deal Related Amortization

Page 2 - Supplemental Information: FY18 Constant Currency Growth Rates

Page 3 - Historical revenue by Product Category

Deal Related Amortization

Supplemental Information - Deal Related Amortization

(\$ Millions, except per Share Data)

	FY15	FY16	FY17	Q118
Deal Amortization	\$ 30	\$ 28	\$ 27	\$ 6
Tax Effect of Deal Amortization	\$ (9)	\$ (8)	\$ (8)	\$ (2)
Deal Amortization, EPS	\$ 0.40	\$ 0.40	\$ 0.38	\$ 0.09

FY18 Product Category Growth Rates in Reported and Constant Currency

	Q1 % Growth - Reported Currency	Q1 % Growth - Constant Currency
Plasma	4.0%	4.3%
Hospital	6.1%	6.9%
Hemostasis Management	14.8%	16.7%
Cell Processing	1.0%	1.5%
Blood Center	(7.6%)	(7.1%)
Total Revenue	0.5%	1.0%

Historical Product Category Growth Rates in Reported Currency

(\$ Millions)

	Q117	Q217	Q317	Q417	FY17	Q118
Total Revenue	\$ 210	\$ 220	\$ 228	\$ 228	\$ 886	\$ 211
<i>By Product Category:</i>						
Plasma	\$ 98	\$ 104	\$ 108	\$ 101	\$ 411	\$ 101
Hospital	\$ 41	\$ 42	\$ 43	\$ 45	\$ 171	\$ 44
Hemostasis Management	\$ 15	\$ 16	\$ 17	\$ 18	\$ 66	\$ 18
Cell Processing	\$ 26	\$ 26	\$ 26	\$ 27	\$ 105	\$ 26
Blood Center	\$ 71	\$ 74	\$ 77	\$ 82	\$ 304	\$ 66